{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:56:43Z","timestamp":1792796203264,"version":"4.5.0"},"reference-count":80,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>Tislelizumab is an anti-programmed death receptor 1 (PD-1) monoclonal immunoglobulin G 4 antibody developed by BeiGene. The structure of tislelizumab has been modified to maximally inhibit the binding of PD-1 to programmed death ligand 1 (PD-L1) and minimize the binding of tislelizumab to Fc\u03b3 receptors. In clinical studies, tislelizumab has shown preliminary anti-tumor effects in various solid tumors, such as Hodgkin\u2019s lymphoma, urothelial carcinoma, lung cancer, gastric and esophageal cancer, liver cancer, nasopharyngeal carcinoma, colorectal cancer, and microsatellite instability-high\/mismatch repair-deficient tumors. In addition, it also showed new promise in solid tumor treatment in combination with ociperlimab. Due to its satisfactory anti-tumor effects, tislelizumab has received approvals in China for the treatment of classical Hodgkin\u2019s lymphoma, urothelial carcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, and hepatocellular carcinoma, and it is now under investigation for a new indication in microsatellite instability-high\/mismatch repair-deficient tumors. Moreover, it has been granted orphan designations in hepatocellular carcinoma, esophageal cancer, and gastric cancer, including cancer of the gastroesophageal junction, by the US Food and Drug Administration. Tislelizumab has an acceptable safety profile; the most common adverse effects include fatigue, anemia, and decreased neutrophil count, while the most fatal events have been related to respiratory infection or failure, and hepatic injury. Tislelizumab has an economic advantage compared with other well-studied PD-1\/PD-L1 inhibitors; thus, the introduction of it could provide clinical oncologists with an effective weapon against tumors and may alleviate the burden of cancer patients.<\/jats:p>","DOI":"10.1177\/10732748221111296","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T15:57:17Z","timestamp":1659628637000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":90,"title":["Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody"],"prefix":"10.1177","volume":"29","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-5084","authenticated-orcid":false,"given":"Qing","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"bibr1-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182"},{"key":"bibr2-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712"},{"key":"bibr3-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118"},{"key":"bibr4-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111876"},{"key":"bibr5-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01286-z"},{"key":"bibr6-10732748221111296","volume-title":"Release Notice of Drug Approvals on April 13, 2020","author":"National Medical Product Administration","year":"2020"},{"key":"bibr7-10732748221111296","volume-title":"Release Notice of Drug Approvals on January 18, 2021","author":"National Medical Product Administration","year":"2021"},{"key":"bibr8-10732748221111296","volume-title":"Release Notice of Drug Approvals on June 22, 2021","author":"National Medical Product Administration","year":"2021"},{"key":"bibr9-10732748221111296","volume-title":"Mailing Details of Drug Receipts on June 22, 2021","author":"National Medical Product Administration","year":"2021"},{"key":"bibr10-10732748221111296","volume-title":"Mailing Details of Drug Receipts on March 18, 2021","author":"National Medical Product Administration","year":"2021"},{"key":"bibr11-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3266-5_23"},{"key":"bibr12-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3266-5_4"},{"key":"bibr13-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.04.121"},{"key":"bibr14-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13102"},{"key":"bibr15-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1038"},{"key":"bibr16-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab314"},{"key":"bibr17-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14369"},{"key":"bibr18-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.77"},{"key":"bibr19-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229206"},{"key":"bibr20-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2160-x"},{"key":"bibr21-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004"},{"key":"bibr22-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-2226"},{"key":"bibr23-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000453"},{"key":"bibr24-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e14560"},{"key":"bibr25-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-5626"},{"key":"bibr26-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30396-1"},{"key":"bibr27-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000437"},{"key":"bibr28-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2"},{"key":"bibr29-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.06.007"},{"key":"bibr30-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681"},{"key":"bibr31-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3561"},{"key":"bibr32-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366"},{"key":"bibr33-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.005"},{"key":"bibr34-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.005"},{"key":"bibr35-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.807"},{"key":"bibr36-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2556"},{"key":"bibr37-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9102"},{"key":"bibr38-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy487"},{"key":"bibr39-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2583"},{"key":"bibr40-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2569"},{"key":"bibr41-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"bibr42-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"bibr43-10732748221111296","volume-title":"Release Notice of Drug Approvals on December 31","author":"National Medical Product Administration","year":"2019"},{"key":"bibr44-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2023"},{"key":"bibr45-10732748221111296","volume-title":"Clinical trials on tislelizumab","author":"U.S. National Library of Medicine","year":"2021"},{"key":"bibr46-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30496-X"},{"key":"bibr47-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"bibr48-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70054-9"},{"key":"bibr49-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"bibr50-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-00909-5"},{"key":"bibr51-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy540"},{"key":"bibr52-10732748221111296","volume-title":"Search Orphan Drug Designations and Approvals","author":"U.S. Food &amp; Drug Administration","year":"2021"},{"key":"bibr53-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5441"},{"key":"bibr54-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6"},{"key":"bibr55-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888"},{"key":"bibr56-10732748221111296","volume-title":"BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma","author":"Beigene news","year":"2021"},{"key":"bibr57-10732748221111296","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0632"},{"key":"bibr58-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2656"},{"key":"bibr59-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00690-0"},{"key":"bibr60-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0863"},{"key":"bibr61-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"bibr62-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"bibr63-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"bibr64-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0388"},{"key":"bibr65-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3675"},{"key":"bibr66-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5595"},{"key":"bibr67-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9128"},{"key":"bibr68-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4150"},{"key":"bibr69-10732748221111296","volume-title":"Search Results for: Tislelizumab and Ociperlimab","author":"U.S. National Library of Medicine","year":"2021"},{"key":"bibr70-10732748221111296","unstructured":"National Institute of Health. Common Terminology Criteria for Adverse Events (CTCAE). 2020. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm Accessed February 24, 2022."},{"key":"bibr71-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226"},{"key":"bibr72-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"bibr73-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"bibr74-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393"},{"key":"bibr75-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00333-8"},{"key":"bibr76-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"bibr77-10732748221111296","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32152-9"},{"key":"bibr78-10732748221111296","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01508"},{"key":"bibr79-10732748221111296","volume-title":"Public consultation of Work plan for the adjustment of the national insurance drug list in 2020 (Draft for Comments)","author":"National Healthcare Security Administration","year":"2020"},{"key":"bibr80-10732748221111296","volume-title":"The notice of issuing <National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2020)>, by National Health Security Administration and Ministry of Human Resouraces and Social Security of the People's Republic of China","author":"National Healthcare Security Administration","year":"2020"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221111296","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748221111296","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221111296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:22:43Z","timestamp":1777386163000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748221111296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":80,"alternative-id":["10.1177\/10732748221111296"],"URL":"https:\/\/doi.org\/10.1177\/10732748221111296","relation":{},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"article-number":"10732748221111296"}}